Vaxcyte Launches $1 Billion Equity and Convertible Notes Offerings
Vaxcyte has commenced underwritten offerings of $500 million in common stock and pre-funded warrants, and $500 million in convertible senior notes due 2032. Both offerings include 30-day over-allotment options.
Vaxcyte commenced underwritten offerings of $500M in common stock and pre-funded warrants, alongside $500M in convertible senior notes due 2032. Each offering includes a 30-day over-allotment option, and completion of one offering is not contingent on the other.